Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yu Mizote is active.

Publication


Featured researches published by Yu Mizote.


International Journal of Cancer | 2012

Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients

Yoshihiro Ohue; Shingo Eikawa; Nami Okazaki; Yu Mizote; Midori Isobe; Akiko Uenaka; Minoru Fukuda; Lloyd J. Old; Mikio Oka; Eiichi Nakayama

The spontaneous immune responses against XAGE‐1b (GAGED2a) were analyzed in non‐small cell lung cancer (NSCLC) patients. An antibody response against XAGE‐1b (GAGED2a) was observed in 10% (20/200) of NSCLC patients and in 19% (13/69) of stage IIIB/IV lung adenocarcinoma patients. A CD4 T‐cell response was detected in 88% (14/16) and a CD8 T‐cell response in 67% (6/9) in the XAGE‐1b (GAGED2a) antibody‐positive patients examined. Frequent antibody responses and CD4 and CD8 T‐cell responses in XAGE‐1b (GAGED2a) antibody‐positive patients indicate the strong immunogenicity of the XAGE‐1b (GAGED2a) antigen in NSCLC patients. We established T‐cell clones from PBMCs of antibody‐positive patients and determined the DRB1*04:05‐restricted XAGE‐1b (GAGED2a) 18–31 peptide (14‐mer) as a CD4 T cell epitope and the A*02:06‐restricted XAGE‐1b (GAGED2a) 21‐29 peptide (9‐mer) as a CD8 T cell epitope. As for peptide recognition, CD4 and CD8 T‐cell clones responded to naturally processed antigen. The CD4 T‐cell clone recognized DCs pulsed with the synthetic protein or a lysate from XAGE‐1b‐transfected 293T cells. The CD8 T‐cell clone showed cytotoxicity against a tumor expressing XAGE‐1b (GAGED2a) and the appropriate HLA class I allele. These findings establish XAGE‐1b (GAGED2a) as a promising target for a lung cancer vaccine.


Journal of Immunotherapy | 2014

Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.

Hisashi Wada; Midori Isobe; Kazuhiro Kakimi; Yu Mizote; Shingo Eikawa; Eiichi Sato; Nagio Takigawa; Katsuyuki Kiura; Kazuhide Tsuji; Keiji Iwatsuki; Makoto Yamasaki; Hiroshi Miyata; Hirokazu Matsushita; Heiichiro Udono; Yasuyuki Seto; Kazuhiro Yamada; Hiroyoshi Nishikawa; Linda Pan; Ralph Venhaus; Mikio Oka; Yuichiro Doki; Eiichi Nakayama

We conducted a clinical trial of an NY-ESO-1 cancer vaccine using 4 synthetic overlapping long peptides (OLP; peptides #1, 79–108; #2, 100–129; #3, 121–150; and #4, 142–173) that include a highly immunogenic region of the NY-ESO-1 molecule. Nine patients were immunized with 0.25 mg each of three 30-mer and a 32-mer long NY-ESO-1 OLP mixed with 0.2 KE Picibanil OK-432 and 1.25 mL Montanide ISA-51. The primary endpoints of this study were safety and NY-ESO-1 immune responses. Five to 18 injections of the NY-ESO-1 OLP vaccine were well tolerated. Vaccine-related adverse events observed were fever and injection site reaction (grade 1 and 2). Two patients showed stable disease after vaccination. An NY-ESO-1-specific humoral immune response was observed in all patients and an antibody against peptide #3 (121–150) was detected firstly and strongly after vaccination. NY-ESO-1 CD4 and CD8 T-cell responses were elicited in these patients and their epitopes were identified. Using a multifunctional cytokine assay, the number of single or double cytokine-producing cells was increased in NY-ESO-1-specific CD4 and CD8 T cells after vaccination. Multiple cytokine-producing cells were observed in PD-1 (−) and PD-1 (+) CD4 T cells. In conclusion, our study indicated that the NY-ESO-1 OLP vaccine mixed with Picibanil OK-432 and Montanide ISA-51 was well tolerated and elicited NY-ESO-1-specific humoral and CD4 and CD8 T-cell responses in immunized patients.


Clinical Cancer Research | 2014

Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.

Yoshihiro Ohue; Koji Kurose; Yu Mizote; Hirofumi Matsumoto; Yumi Nishio; Midori Isobe; Minoru Fukuda; Akiko Uenaka; Mikio Oka; Eiichi Nakayama

Purpose: The cancer/testis antigen XAGE1 (GAGED2a) is expressed in approximately 40% of advanced lung adenocarcinomas. We investigated the clinical relevance of the XAGE1 (GAGED2a) immune responses in patients with advanced lung adenocarcinoma. Experimental Design: The XAGE1 (GAGED2a) antigen expression and EGFR mutation were determined with tumor tissues. The XAGE1 (GAGED2a) antibody and T-cell immune responses, as well as immune cell phenotypes, were analyzed with blood samples. Patients with EGFR wild-type (EGFRwt) tumors were treated with conventional platinum-based doublet chemotherapy and patients with EGFR-mutated (EGFRmt) tumors were treated with EGFR-TKI and conventional chemotherapy. The overall survival (OS) rates of the antibody-positive and -negative patients were investigated. Results: The results showed that the OS of antibody-positive patients was prolonged significantly compared with that of antibody-negative patients with either XAGE1 (GAGED2a) antigen-positive EGFRwt (31.5 vs. 15.6 months, P = 0.05) or EGFRmt (34.7 vs. 11.1 months, P = 0.001) tumors. Multivariate analysis showed that the presence of the XAGE1 (GAGED2a) antibody was a strong predictor for prolonged OS in patients with XAGE1 (GAGED2a) antigen-positive tumors and in patients with either EGFRwt or EGFRmt tumors. On the other hand, XAGE1 (GAGED2a) antigen expression was a worse predictor in patients with EGFRmt tumors. Phenotypic and functional analyses of T cells indicated immune activation in the antibody-positive patients. Conclusions: The findings suggest that production of the XAGE1 (GAGED2a) antibody predicts good prognosis for patients with lung adenocarcinoma as an immune biomarker and the protective effect of this naturally occurring immune response supports the concept of immunotherapy. Clin Cancer Res; 20(19); 5052–63. ©2014 AACR.


Cancer Research | 2013

Abstract 4732: Depletion of Tregs from PBMCs by treatment with defucosylated anti-CCR4 mAb.

Koji Kurose; Shingo Eikawa; Yu Mizote; Yoshihiro Ohue; Midori Isobe; Akiko Uenaka; Mikio Oka; Eiichi Nakayama

Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Objectives: Tregs down-regulate immune responses against various antigens including tumor cells. Impairment of Tregs cause autoimmune responses. CC chemokine receptor 4 (CCR4) is expressed selectively on Foxp3+CD4 T-cells, so that the treatment of PBMCs with KM2760, anti-human CCR4 mAb with a defucosylated Fc region, could deplete CCR4+Tregs by ADCC. In this study, we analyzed depletion of Tregs phenotypically and functionally after treatment of PBMCs with KM2760. Methods and main results: CCR4 expression was analyzed on CD4 T-cells purified from healthy donor PBMCs by FACS. CCR4 positivecells were 21% in CD4 T-cells, and 71% in Foxp3+cells. Depletion of CCR4 positive cells by treatment with KM2760 was examined. PBMCs were incubated with KM2760 (0, 0.01, 0.1, 1, 10 μg/ml) for 4 or 20 hours, and analyzed by FACS. Efficient depletion was observed with higher antibody concentration and longer incubation time. Then we examined inhibition of CFSE dilution of labeled CD4 or CD8 T cells stimulated with anti-CD3 mAb after culture with an equal number of CD4+25+127low Tregs and CD4-8- cells pretreated with or without KM2760. Proliferating responder cells were 68% in culture with CD4+25+127low Tregs pretreated with KM2760, whereas those cells with CD4+25+127low Tregs without pretreatment was 38% in CD4 T-cells, 77%and 40% in CD8 T-cells,respectively. Conclusions: Efficient Treg depletion was observed in vitro by treatment of PBMCs with KM2760. In vivo treatment with the same mAb may induce tumor immune responses by Treg depletion. Citation Format: Koji Kurose, Shingo Eikawa, Yu Mizote, Yoshihiro Ohue, Midori Isobe, Akiko Uenaka, Mikio Oka, Eiichi Nakayama. Depletion of Tregs from PBMCs by treatment with defucosylated anti-CCR4 mAb. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4732. doi:10.1158/1538-7445.AM2013-4732


Vaccine | 2014

Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.

Yu Mizote; Akiko Uenaka; Midori Isobe; Hisashi Wada; Kazuhiro Kakimi; Takashi Saika; Shoichi Kita; Yukari Koide; Mikio Oka; Eiichi Nakayama

We established CD4 T-cell clones, Mz-1B7, and Ue-21, which recognized the NY-ESO-1 121-138 peptide from peripheral blood mononuclear cells (PBMCs) of an esophageal cancer patient, E-2, immunized with an NY-ESO-1 protein and determined the NY-ESO-1 minimal epitopes. Minimal peptides recognized by Mz-1B7 and Ue-21 were NY-ESO-1 125-134 and 124-134, respectively, both in restriction to DRB1*08:03. Using a longer peptide, 122-135, and five other related peptides, including either of the minimal epitopes recognized by the CD4 T-cell clones, we investigated the free peptide/DR recognition on autologous EBV-B cells as APC and peptide/DR tetramer binding. The results showed a discrepancy between them. The tetramers with several peptides recognized by either Mz-1B7 or the Ue-21 CD4 T-cell clone did not bind to the respective clone. On the other hand, unexpected binding of the tetramer with the peptide not recognized by CD4 T-cells was observed. The clone Mz-1B7 did not recognize the free peptide 122-135 on APC, but the peptide 122-135/DRB1*08:03 tetramer bound to the TCR on those cells. The failure of tetramer production and the unexpected tetramer binding could be due to a subtly modified structure of the peptide/DR tetramer from the structure of the free peptide/DR molecule. We also demonstrated that the NY-ESO-1 123-135/DRB1*08:03 tetramer detected ex vivo CD4 T-cell responses in PBMCs from patients after NY-ESO-1 vaccination in immunomonitoring.


Journal of Dermatological Science | 2014

TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD).

Yu Mizote; Kazumasa Wakamatsu; Shosuke Ito; Akiko Uenaka; Yoshihiro Ohue; Koji Kurose; Midori Isobe; Akira Ito; Yasuaki Tamura; Hiroyuki Honda; Toshiharu Yamashita; Satoshi Nohara; Mikio Oka; Kowichi Jimbow; Eiichi Nakayama

BACKGROUND N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD) is a toxic tyrosinase substrate developed to treat melanoma. OBJECTIVE We investigated the effect of NPCMD on innate immune responses in monocytes. METHODS CD14⁺ monocytes and a monocytic cell line, THP-1, were stimulated with NPCMD in vitro. Cytokines in the culture supernatants were determined by ELISA and flow cytometry. RESULTS NPCMD stimulated CD14⁺ monocytes and THP-1 cells to secrete TNFα, IL-6 and IL-8, but not IL-10 or IL-12. TNFα secretion from THP-1 cells stimulated with NPCMD was inhibited by addition of an anti-TLR4 mAb in culture. Moreover, NPCMD stimulated production of pro-IL-1β in CD14⁺ monocytes and monocytic cell line THP-1 cells and activated the NLRP3-inflammasome, resulting in production of mature IL-1β. Use of ASC and NLRP3-deficient THP-1 cell lines established involvement of the NLRP3 inflammasome in an IL-1β secretion in treatment with NPCMD. Inhibition of IL-1β secretion by an endocytosis inhibitor, cytochalasin B, and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested the involvement of lysosomal rupture and leakage of cathepsin B into the cytosol in NLRP3 activation by NPCMD. CONCLUSION The immunopotentiating effect of NPCMD mediated by TLR4 and NLRP3 inflammasome activation could be useful for eliciting effective adaptive immune responses against melanoma and other tumors.


Cancer Research | 2013

Abstract 495: Immune response to XAGE-1b (GAGED2a) in NSCLC patients and its clinical relevance.

Yoshihiro Ohue; Koji Kurose; Shingo Eikawa; Yu Mizote; Hirofumi Matsumoto; Midori Isobe; Akiko Uenaka; Minoru Fukuda; Eiichi Nakayama; Mikio Oka

BACKGROUND:XAGE-1bis a cancer/testis (CT) antigen expressed highly in non-small cell lung cancer (NSCLC) with restricted expressiononly in testis in normal tissues. In this study, we investigated correlation of intensity of humoral and cellular immune responses against XAGE-1b and itsclinical relevance in NSCLC patients. MATERIALS AND METHODS:Peripheral bloodwas obtained from NSCLC patients who visited Kawasaki Medical School Hospital between 2005 and 2012 under written informed consent. Antibody response to XAGE-1bwas analyzed by ELISA using synthesized XAGE-1b protein. CD4 and CD8 T-cell responses were examined by IFN-γ ELISA and/or IFN-γcapture assay by FACS using 12-mer or 16-merXAGE-1b-overlapping peptides (OLPs) spanning the entire XAGE-1b (GAGED2a) protein. RESULTS: Antibody positive frequencies of total 362 NSCLC, 220 lung adenocarcinoma and 85 lung squamous cell carcinoma patients were 8.8% (32/362), 12.7% (28/220) and 1.2% (1/85), respectively. With antibody positive NSCLC patients, the patients showing high, intermediate and low antibody response was 7, 20 and 5, respectively. The frequency of XAGE-1b-reactive CD4 T-cells in patients showing high, intermediate and low antibody response was 5.5 ±2.1 x 10 − 5 , 1.5 ±0.7 x 10 − 5 and − 5 , respectively. The frequency of XAGE-1b-reactive CD8 T-cells was 6.9 ±1.6 x 10 − 6 , 4.6 ±1.6 x 10 − 6 and − 6 , respectively. The frequency of cytotoxic CD8 T-cells in IFN-γ secreting CD8 T-cells in response to XAGE-1b-peptide-pulsed autologous EBV-B cells in patients showing high and intermediate antibody responses was 59.0% and 4.8%, respectively.We evaluated overall survival (OS) time with 120 stage IIIB/IV lung adenocarcinoma patients. Median OS were 32.3 and 14.4 months in antibody-positive and negative patients(P-.039). There was no significant differencewith 1-year survival rate in antibody-positive (68.7%) and negative (55.6%)patients, but was significant with 3-year survival rate in 34.8% and 14.1% respectively. Furthermore, univariate and multivariable analyses showed XAGE-1b antibody response was independent prognostic factor. CONCLUSION:Our findings indicate that CT antigen XAGE-1b is highly immunogenic in NSCLC patients inducing antibody, and CD4 and CD8 T-cell responses and the immune response against XAGE-1b is beneficial for prognosis. Citation Format: Yoshihiro Ohue, Koji Kurose, Shingo Eikawa, Yu Mizote, Hirofumi Matsumoto, Midori Isobe, Akiko Uenaka, Minoru Fukuda, Eiichi Nakayama, Mikio Oka. Immune response to XAGE-1b (GAGED2a) in NSCLC patients and its clinical relevance. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 495. doi:10.1158/1538-7445.AM2013-495


Cancer Research | 2012

Abstract 508: Correlation of antibody and T-cell responses against XAGE-1b in NSCLC patients

Yoshihiro Ohue; Shingo Eikawa; Yu Mizote; Hirofumi Matsumoto; Midori Isobe; Minoru Fukuda; Akiko Uenaka; Eiichi Nakayama; Mikio Oka

Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL BACKGROUND: XAGE-1b is a cancer/testis antigen identified in lung cancer using autologous patient serum by SEREX. The expression of XAGE-1b is observed frequently in lung adenocarcinoma and rarely in some other tumors. Recently, we showed spontaneous T-cell response against XAGE-1b in XAGE-1b-antibody positive non-small cell lung cancer (NSCLC) patients. In this study, we analyzed the frequency of XAGE-1b-reactive CD4 and CD8 T-cells in NSCLC patients showing high, intermediate and low antibody responses. MATERIALS AND METHODS: Sera and PBMCs were obtained from NSCLC patients who visited Kawasaki Medical School Hospital between 2009 and 2011. Antibody response was determined for XAGE-1b protein by ELISA using O.D. values at 1:900 serum dilution and classified as high ≥ 3.0, 3.0 > intermediate ≥ 1.0 and 1.0 > low. CD4 and CD8 T-cell responses against XAGE-1b were examined by IFN-γ ELISA using 12- or 16-mer XAGE-1b-overlapping peptides (OLPs) spanning the entire XAGE-1b protein in antibody-positive patients. Cytotoxicity was analyzed determining GAPDH release by aCellaTox kit. RESULTS: The number of XAGE-1b-antibody positives was 29 (9.0%) of 323 NSCLC patients. Within those, the patients showing high, intermediate and low antibody response was 6, 11 and 12, respectively. The frequency of XAGE-1b-reactive CD4 T-cells in patients showing high, intermediate and low antibody response was 5.5 ±2.1 x 10-5, 1.5 ±0.7 x 10-5 and < 1.1 x 10-5, respectively. The frequency of XAGE-1b reactive CD8 T-cells was 6.9 ±1.6 x 10-6, 4.6 ±1.6 x 10-6 and < 1.1 x 10-6, respectively. The ratio of the CD8 T-cells recognizing XAGE-1b-expressing tumor to the XAGE-1b-peptide reactive CD8 T-cells in patients showing high and intermediate antibody responses was 60.0% and 14.3%, respectively. CONCLUSION: Our findings indicate correlation of antibody response to CD4 and CD8 T-cell responses against XAGE-1b in NSCLC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 508. doi:1538-7445.AM2012-508


Cancer Research | 2012

Abstract 518: Immunogenicity of cancer/testis antigen XAGE-1d in patients with non-small cell lung cancer (NSCLC)

Hirofumi Matsumoto; Yoshihiro Ohue; Shingo Eikawa; Yu Mizote; Koji Kurose; Midori Isobe; Akiko Uenaka; Takeshi Nagayasu; Mikio Oka; Eiichi Nakayama

Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL BACKGROUND: Cancer/testis (CT) antigens expresses in various cancers and normal testis. Because of no expression of HLA class-I antigen in normal testis, CT antigens are promising molecular target for specific cancer immunotherapy. XAGE-1 gene has been identified as a CT-like antigen, and XAGE-1 gene has four alternative splice variants: XAGE-1a, XAGE-1b, XAGE-1c, and XAGE-1d. We previously reported that the transcript of XAGE-1a and XAGE-1b coded the same protein (GAGED2, isoform a, 81 amino acids) and the transcript of XAGE-1d coded another protein (GAGED2, isoform b, 69 amino acids). The first half of XAGE-1b and 1d protein (1-32 amino acids) is same sequence. On the other hand, XAGE-1c transcript codes some peptides but not a protein. Previously, immunogenic analyses of XAGE-1b have been performed because of its dominant expression, however, few analysis of XAGE-1d was performed. In this study, we investigated the immunogenicity of XAGE-1d in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Tumor tissue samples for extracting mRNA were obtained from NSCLC patients treated surgical resection at Nagasaki University Hospital during the period from 2005 to 2010. Sera and PBMCs were obtained from NSCLC patients who visited Kawasaki Medical School Hospital during the period from 2005 to 2010. Splising variants of XAGE-1 gene were analyzed by quantitative real-time PCR with specific TaqMan probe-primer sets. Antibody responses to XAGE-1d were analyzed by ELISA using synthesized XAGE-1b protein. In antibody-positive patients, CD4+ T-cell responses against XAGE-1d were examined by IFN-γ ELISA. Epitope-peptides recognized by XAGE-1d specific T-cells were determined by ELISA using XAGE-1d-overlapping peptides (OLPs). RESULTS: In quantitative real-time PCR, expression of XAGE-1d mRNA was observed in 16/38 specimens (42.1%) that were also positive with XAGE-1b mRNA. The correlation coefficiency of the expression was 0.8047. Protein expression of XAGE-1d was observed in cytoplasm, being different from that of XAGE-1b in the nucleus in lung cancer cell lines by immunohistochemical staining. Antibody against XAGE-1d was detected in lung cancer patients who were also positive with XAGE-1b antibody. By a limiting dilution, a CD4+ T-cell clone was obtained from PBMCs in a seropositive patient. HLA class II restricted recognition of XAGE-1d was confirmed using various allogeneic EBV-B cells as APC. 14-mer minimal epitope peptide was determined. CONCLUSION: The findings indicate that XAGE-1d co-expresses with XAGE-1b and is immunogenic in NSCLC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 518. doi:1538-7445.AM2012-518


Cancer Research | 2011

Abstract 2689: XAGE-1b(GAGED2a) immunity in non-small cell lung cancer

Yoshihiro Ohue; Shingo Eikawa; Hirofumi Matsumoto; Yu Mizote; Midori Isobe; Akiko Uenaka; Minoru Fukuda; Eiichi Nakayama; Mikio Oka

Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL BACKGROUND: Several cancer/testis(CT) antigens such as NY-ESO-1 antigen, etc., have been shown to elicit immune responses in cancer patients spontaneously. Because of their restricted expression in normal tissues and high immunogenicity, CT antigens have been thought to be attractive targets for cancer vaccine. We previously described XAGE-1b (GAGED2a), one of the CT-associated antigens, was predominantly expressed in lung adenocarcinoma by immunohistochemistry using XAGE-1b mAb (clone USO 9-13) and could elicit both humoral and cellular immune response in patients with non-small cell lung cancer (NSCLC). In this study, we established CD4 and CD8 T cell clones from PBMC in XAGE-1b antibody-positive patients and analyzed the antigen recognition. MATERIALS AND METHODS: Sera and PBMCs were obtained from NSCLC patients who visited Kawasaki Medical School Hospital between 2005 and 2010. Antibody response to XAGE-1b was analyzed by ELISA using synthesized XAGE-1b protein. CD4 and CD8 T cell responses against XAGE-1b were examined by IFN-γ ELISA and/or capture assay using 17 16- or 17-mer XAGE-1b-overlapping peptides (OLPs) spanning the entire XAGE-1b protein by FACS in antibody-positive patients. Cytotoxicity was analyzed by bioluminescence assay (GAPDH). RESULTS: Spontaneous CD4 and CD8 T cell responses were also detected in most of the antibody positive patients. Occurrence of antibody response, and CD4 and CD8 T cell responses in XAGE-1b (GAGED2a) antibody positive patients indicated strong immunogenicity of XAGE-1b (GAGED2a) antigen in NSCLC patients. Furthermore, We identified the minimal epitope peptide bound to HLA-DR4.1 and DP5 recognized by CD4 and those bound to HLA-A2, B61 and Cw1 recognized by CD8 T cell clones. CD4 and CD8 T cell clones recognized naturally processed XAGE-1b (GAGED2a) antigen on APC (antigen-presenting cell) and the CD8 T cell clone was stained with the peptide/MHCI tetramer and showed cytotoxicity against XAGE-1b (GAGED2a)-expressing, appropriate HLA class I expressing tumor cell line. CONCLUSION: Our findings indicate validity of XAGE-1b (GAGED2a) for cancer vaccine. Now we plan to global clinical trial of cancer vaccine against XAGE-1b in NSCLC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2689. doi:10.1158/1538-7445.AM2011-2689

Collaboration


Dive into the Yu Mizote's collaboration.

Top Co-Authors

Avatar

Eiichi Nakayama

Kawasaki University of Medical Welfare

View shared research outputs
Top Co-Authors

Avatar

Midori Isobe

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mikio Oka

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Koji Kurose

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge